About Alzamend Neuro
Alzamend Neuro (NASDAQ:ALZN) is dedicated to researching, developing, and commercializing innovative treatments for neurodegenerative diseases and psychiatric disorders, with a primary focus on Alzheimer's disease. The company is committed to addressing the vast unmet medical needs in mental health and neurology, aiming to improve the lives of patients suffering from debilitating conditions. Alzamend Neuro is driven by a long-term strategy that focuses on advancing its pipeline of promising therapeutic candidates from research through to clinical trials, with the ultimate goal of bringing new and effective options to the market. The company endeavors to partner with leading research institutions and leverage cutting-edge science in its quest to deliver groundbreaking therapies.
Snapshot
Operations
Produtos e/ou serviços de Alzamend Neuro
- AL001, a lithium-based ionic cocrystal therapy aimed at halting the progression of Alzheimer's disease.
- AL002, a patented mutant-peptide vaccine for both treatment and prevention of Alzheimer's.
- A diagnostic tool for early detection and management of Alzheimer's and other neurodegenerative diseases.
- Technology platforms for enhancing drug delivery to the brain.
- Collaborations with academic and research institutions for Alzheimer's disease research.
- Partnerships for the development of AI and machine learning models to predict disease progression.
equipe executiva do Alzamend Neuro
- Mr. Stephan JackmanCEO & Director
- Mr. Milton Charles Ault IIIFounder & Vice Chairman
- Mr. David J. KatzoffChief Financial Officer
- Mr. Henry C. W. Nisser Esq.Executive VP, General Counsel & Director
- Mr. Kenneth S. Cragun CPASenior Vice President of Finance